CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
蛋白酶体抑制剂联合免疫治疗：多发性骨髓瘤中的最新进展
英文原题：Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
查看英文原题
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种恶性浆细胞疾病，约占所有肿瘤性疾病的1.8%。目前临床医生可使用多类药物治疗MM，包括蛋白酶体抑制剂、免疫调节药物、单克隆抗体、双特异性抗体、CAR-T 细胞疗法和抗体药物偶联物。本文简要介绍硼替佐米、卡非佐米和伊沙佐米等蛋白酶体抑制剂相关的重要临床要点。研究提示，较早应用免疫治疗可能显著改善结局。因此，本文特别关注蛋白酶体抑制剂与新型免疫疗法和/或移植的联合治疗。许多患者会对蛋白酶体抑制剂产生耐药。本文还综述新一代蛋白酶体抑制剂，如马里佐米、奥普佐米（ONX0912）和德兰佐米（CEP-18770），以及它们与免疫疗法的联合方案。
展开英文摘要原文
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1. 8% of all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal for the treatment of MM, such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates.
In this paper we briefly highlight essential clinical elements relating to proteasome inhibitors, such as bortezomib, carfilzomib and ixazomib. Studies suggest that the early use of immunotherapy may improve outcomes significantly.
Therefore, in our review we specifically focus on the combination therapy of proteasome inhibitors with novel immunotherapies and/or transplant. A high number of patients develop PI resistance.
Thus, we also review new generation PIs, such as marizomib, oprozomib (ONX0912) and delanzomib (CEP-18770) and their combinations with immunotherapies.
论文信息
- 作者
- Kegyes D、Gulei D、Drula R、Cenariu D、Tigu B、Dima D、Tanase A、Badelita S
- 第一作者单位
- Medfuture Research Center for Advanced Medicine / Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.Italy
- 通讯作者单位
- Medfuture Research Center for Advanced Medicine / Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania. Electronic address: Ciprian.tomuleasa@gmail.com.Italy
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Blood reviews2023 Sep
- 原文标识
- PubMed 37291017 · DOI 10.1016/j.blre.2023.101100